{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-063368","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.844389+00:00","generated_at":"2026-06-08T03:58:36.705676+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Terns Pharma Q3 net loss $29.8M; advances TERN-701 CML trial, TERN-601 obesity trial","bullets":["Net loss $29.8M ($0.42/sh) vs $16.8M ($0.44/sh) in Q3 2022; G&A expenses surged to $18.4M from $5.1M.","Cash $266.6M as of Sep 30, 2023 vs $283.1M at Dec 31, 2022; expected runway into 2026.","Phase 1 global trial (CARDINAL) of TERN-701 (allosteric BCR-ABL) for CML cleared; screening starts Dec 2023; interim data H2 2024.","First participant dosed in Phase 1 trial of TERN-601 (oral GLP-1) for obesity; 28-day proof-of-concept data expected H2 2024.","Positive Phase 2a DUET data for TERN-501 (THR-β) in NASH met all primary/secondary endpoints."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-063368","json":"https://secwatch.observer/filing/0000950170-23-063368.json","markdown":"https://secwatch.observer/filing/0000950170-23-063368.md","text":"https://secwatch.observer/filing/0000950170-23-063368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023063368/0000950170-23-063368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023063368/tern-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:58:36.705676+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f307c1831e03a1459a95fb197d21f9c9aa081184","claim":"Terns Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023063368/0000950170-23-063368-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}